ArticleClinical, cosmetic and investigational dermatology2025
Successful Treatment of Refractory Livedoid Vasculopathy with Upadacitinib: A Case Report.
Article in Clinical, cosmetic and investigational dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- JAK-Inhibitors Beyond the Label: Emerging Applications in Dermatology.Medicina (Kaunas, Lithuania) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: While tofacitinib, baricitinib, and abrocitinib demonstrate efficacy in livedoid vasculopathy (LV), this study evaluates upadacitinib-a distinct Janus kinase (JAK) inhibitor-in refractory LV. Patients and Methods: A 54-year-old female with treatment-resistant LV received upadacitinib (15 mg/day). Treatment response was assessed via composite clinical scores pre- and post-therapy. Results: Significant improvement occurred within 24 days (score: 7→2), indicating remission. Pain intensity markedly decreased, and near-complete ulcer healing was observed by day 52. No adverse effects were observed, with the exception of orolabial herpes simplex. Conclusion: Upadacitinib represents a novel therapeutic alternative for LV. Larger cohorts are needed to validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.